ReviewJournal of diabetes investigation2026
A review of capillary β-hydroxybutyrate cut-off levels for the exclusion and identification of diabetic ketoacidosis.
Review in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionDiabetic ketoacidosis (DKA) is an acute, life-threatening emergency that can arise as a complication of diabetes mellitus. We sought to examine the literature regarding capillary β-OHB testing levels that can inform cut-offs and help clinicians to safely and effectively exclude or identify DKA. MATERIALS AND
methodsFor this narrative review with a systematic approach, MEDLINE, Embase, and Emcare databases were searched for primary studies. Included studies described capillary β-OHB levels in relation to suspected DKA, for populations aged ≥16 years. Exclusion criteria were non-English language, animal studies or case reports, and/or exclusive focus on serum β-OHB.
resultsOf the 1,177 records identified, 11 studies met the criteria for data extraction. To exclude DKA in patients with hyperglycemia, capillary β-OHB cut-off values of <1.0 mmol/L and <1.5 mmol/L were most recommended. A capillary β-OHB level >3.0 mmol/L exhibited high sensitivity and specificity in detecting DKA and may be used in identifying cases of DKA.
conclusionsCapillary testing can reliably detect β-OHB levels within the DKA diagnostic threshold. While a capillary β-OHB threshold of <1.5 mmol/L may help clinicians exclude DKA, a capillary β-OHB level >3.0 mmol/L showed high sensitivity and specificity in detecting DKA. Future studies are needed to validate proposed cut-offs and examine the utility of capillary β-OHB testing in prehospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.